期刊
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
卷 13, 期 2, 页码 191-192出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00042737-200102000-00016
关键词
Crohn's disease; hepatitis C; infliximab; tumour necrosis factor alpha
Treatment of Crohn's disease with infliximab is an important drug therapy for patients with refractory and fistulating disease. There are concerns over its use in a proportion of Crohn's patients with concurrent hepatitis C infection, since there are theoretical risks of accelerated hepatic decompensation due to the immunomodulatory impact of infliximab. We report a patient with both Crohn's disease and ongoing active hepatitis C infection who underwent infliximab therapy, with no worsening of his liver function or PCR status. Eur J Gastroenterol Hepatol 13:191-192 (C) 2001 Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据